|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...10401041104210431044104510461047104810491050...10631064» |
- |||||||||| DuoResp Spiromax (budesonide/formoterol) / Teva
New P3 trial: Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX (clinicaltrials.gov) - Feb 28, 2013
P3, N=600, Recruiting, Sponsor: Teva Pharmaceutical Industries
- | Tavegil (clemastine) / GSK
Enrollment open, Head-to-Head: Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment (clinicaltrials.gov) - Feb 28, 2013
P3, N=30, Recruiting, Sponsor: EMS
Not yet recruiting --> Recruiting
- |||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Enrollment open: Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg (clinicaltrials.gov) - Feb 27, 2013
P4, N=400, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Veramyst (fluticasone furoate nasal spray) / GSK
Enrollment open: A Dose-ranging Study of Fluticasone Furoate (FF) (clinicaltrials.gov) - Feb 27, 2013
P2, N=575, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Veramyst (fluticasone furoate nasal spray) / GSK
Trial completion: Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma (clinicaltrials.gov) - Feb 27, 2013
P3, N=248, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Completed
- | tobramycin/dexamethasone / Generic mfg.
New P4 trial: Efficacy Comparison Study of Steroids to Control Post-operative Inflammation (clinicaltrials.gov) - Feb 27, 2013
P4, N=140, Recruiting, Sponsor: Mahidol University
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 27, 2013
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Incruse Ellipta (umeclidinium) / GSK, Veramyst (fluticasone furoate nasal spray) / GSK
Trial completion: To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI) (clinicaltrials.gov) - Feb 27, 2013
P1, N=18, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- TroVax (MVA 5T4) / Oxford Biomedica
Trial initiation date: SKOPOS: A Phase II Trial to Assess TroVax (clinicaltrials.gov) - Feb 26, 2013
P2, N=26, Recruiting, Sponsor: Wales Cancer Trials Unit
Active, not recruiting --> Completed Initiation date: Apr 2012 --> Dec 2012
- TroVax (MVA 5T4) / Oxford Biomedica
Enrollment open: SKOPOS: A Phase II Trial to Assess TroVax (clinicaltrials.gov) - Feb 26, 2013
P2, N=26, Recruiting, Sponsor: Wales Cancer Trials Unit
Initiation date: Apr 2012 --> Dec 2012 Not yet recruiting --> Recruiting
- | Ozurdex (dexamethasone intravitreal implant) / AbbVie
Enrollment closed: Ozurdex for Macular Edema Post Membrane Peeling (clinicaltrials.gov) - Feb 26, 2013
P2/3, N=36, Active, not recruiting, Sponsor: Retina Specialists, PC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Enrollment closed, Combination therapy: Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients (clinicaltrials.gov) - Feb 26, 2013
P3, N=660, Active, not recruiting, Sponsor: Fondazione Neoplasie Sangue Onlus
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- midazolam hydrochloride / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: Single Dose of Etomidate and Adrenal Cortex (clinicaltrials.gov) - Feb 25, 2013
P4, N=90, Completed, Sponsor: Istanbul University
Recruiting --> Active, not recruiting N=60 --> 90
- Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial withdrawal: A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise (clinicaltrials.gov) - Feb 21, 2013
P3, N=0, Withdrawn, Sponsor: GlaxoSmithKline
N=60 --> 90 Not yet recruiting --> Withdrawn
- Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Enrollment change: A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise (clinicaltrials.gov) - Feb 21, 2013
P3, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Not yet recruiting --> Withdrawn N=104 --> 0
- dexamethasone / Generic mfg.
Clinical: Effects of Dry Eye Treatments on the Ocular Surface (clinicaltrials.gov) - Feb 21, 2013
P=N/A, N=30, Recruiting, Sponsor: Baylor College of Medicine
- Restylane / Bausch Health, Kenalog-10 (triamcinolone acetonide) / BMS
Clinical: Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata (clinicaltrials.gov) - Feb 20, 2013
P=N/A, N=10, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
- |||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial completion, HEOR: Asthma Comparative Effectiveness Study (clinicaltrials.gov) - Feb 20, 2013
P4, N=6086, Completed, Sponsor: AstraZeneca
N=104 --> 0 Active, not recruiting --> Completed
- ||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial completion: Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients (clinicaltrials.gov) - Feb 20, 2013
P=N/A, N=7779, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion: Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma (clinicaltrials.gov) - Feb 20, 2013
P2, N=14, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
New P3 trial: Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients (clinicaltrials.gov) - Feb 19, 2013
P3, N=16, Completed, Sponsor: FluidDA nv
- | Nulojix (belatacept) / BMS
Enrollment change: Belatacept Post Depletional Repopulation to Facilitate Tolerance (clinicaltrials.gov) - Feb 19, 2013
P2, N=40, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed N=20 --> 40
- | abiraterone acetate / Generic mfg., docetaxel / Generic mfg.
New P2 trial, Metastases: A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel (clinicaltrials.gov) - Feb 19, 2013
P2, N=47, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- | Nulojix (belatacept) / BMS
Enrollment open: Belatacept Post Depletional Repopulation to Facilitate Tolerance (clinicaltrials.gov) - Feb 19, 2013
P2, N=40, Recruiting, Sponsor: Emory University
N=20 --> 40 Active, not recruiting --> Recruiting
- ||| Onbrez (indacaterol) / Novartis
Clinical: A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator (clinicaltrials.gov) - Feb 18, 2013
P=N/A, N=10000, Recruiting, Sponsor: Novartis Pharmaceuticals
- | dexamethasone / Generic mfg.
New P4 trial: Invloed van dexamethasone op postoperatieve pijnstilling na gecombineerde spinale-epidurale anesthesie voor keizersnede. (EUDRACT) - Feb 18, 2013
P4, N=150, Ongoing, Sponsor: AZ Groeninge
- | Venclexta (venetoclax) / Roche, AbbVie
New P1 trial: BELLINI: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 18, 2013
P1, N=30, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- | Venclexta (venetoclax) / Roche, AbbVie
New P1 trial: A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (clinicaltrials.gov) - Feb 18, 2013
P1, N=30, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- | Anoro Ellipta (umeclidinium/vilanterol) / Innoviva, GSK
Enrollment change: Study to compare umeclidinium/vilanterol compared with fluticasone propionate/salmeterol in COPD (EUDRACT) - Feb 17, 2013
P3, N=710, Ongoing, Sponsor: GlaxoSmithKline Research & Development Ltd`GlaxoSmithKline, S.A.
Active, not recruiting --> Recruiting N=202 --> 710
- |||||| Odactra (house dust mite allergy vaccine tablet) - ALK / Abello, Merck (MSD)
Enrollment open: Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607) (clinicaltrials.gov) - Feb 17, 2013
P3, N=1500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=202 --> 710 Not yet recruiting --> Recruiting
- dovitinib (TKI258) / Novartis, Oncoheroes
Trial withdrawal, Combination therapy: Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 17, 2013
P1, N=0, Withdrawn, Sponsor: University of Florida
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- dovitinib (TKI258) / Novartis, Oncoheroes
Trial initiation date, Combination therapy: Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 17, 2013
P1, N=0, Withdrawn, Sponsor: University of Florida
Not yet recruiting --> Withdrawn Initiation date: Oct 2012 --> Feb 2013
- dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment change, Combination therapy: Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 17, 2013
P1, N=0, Withdrawn, Sponsor: University of Florida
Initiation date: Oct 2012 --> Feb 2013 N=40 --> 0
- methylprednisolone sodium succinate / Generic mfg.
Clinical: POMEVAR: Preoperative Methylprednisolone in Endovascular Aortic Repair (clinicaltrials.gov) - Feb 17, 2013
P=N/A, N=150, Active, not recruiting, Sponsor: Louise de la Motte
N=40 --> 0 Recruiting --> Active, not recruiting
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Trial completion, Metastases: A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies (clinicaltrials.gov) - Feb 17, 2013
P1/2, N=12, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Completed
- Veramyst (fluticasone furoate nasal spray) / GSK
Observational data, Trial termination: Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting (clinicaltrials.gov) - Feb 14, 2013
P=N/A, N=3, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Terminated; Insufficient number of patient records met inclusion criteria
- capecitabine / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Metastases: GTX Regimen for Biliary Cancers (clinicaltrials.gov) - Feb 14, 2013
P2, N=4, Terminated, Sponsor: Columbia University
Active, not recruiting --> Terminated; Insufficient number of patient records met inclusion criteria N=43 --> 4
- | lenalidomide / Generic mfg.
New P2 trial: Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide (clinicaltrials.gov) - Feb 14, 2013
P2, N=41, Recruiting, Sponsor: Mayo Clinic
- PF-06291874 / Pfizer
New P1 trial: Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects (clinicaltrials.gov) - Feb 14, 2013
P1, N=8, Completed, Sponsor: Pfizer
- | midazolam hydrochloride / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: Single Dose of Etomidate and Adrenal Cortex (clinicaltrials.gov) - Feb 13, 2013
P4, N=90, Completed, Sponsor: Istanbul University
- || Rituxan (rituximab) / Roche
Enrollment change: NCI-2018-01851: Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 13, 2013
P1, N=110, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=43 --> 4 N=90 --> 110
- | carfilzomib / Generic mfg.
Clinical: Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma (clinicaltrials.gov) - Feb 13, 2013
P1/2, N=38, Recruiting, Sponsor: Oncotherapeutics
- pegylated liposomal doxorubicin / Generic mfg., lenalidomide / Generic mfg.
Enrollment change: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - Feb 12, 2013
P2, N=57, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=90 --> 110 N=20 --> 57
- | Sylvant (siltuximab) / Jazz
Enrollment closed: Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - Feb 11, 2013
P1/2, N=11, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=20 --> 57 Recruiting --> Active, not recruiting
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial initiation date: GLOW8: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (clinicaltrials.gov) - Feb 10, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Jan 2013 --> Apr 2013
- fluticasone propionate inhalation powder / Generic mfg.
Enrollment change: MethaCholine Bronchoprovocation Study (MeCIS) (clinicaltrials.gov) - Feb 10, 2013
P4, N=219, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Initiation date: Jan 2013 --> Apr 2013 N=140 --> 219
- methylprednisolone sodium succinate / Generic mfg.
Clinical: Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) (clinicaltrials.gov) - Feb 10, 2013
P2, N=20, Active, not recruiting, Sponsor: Saratov State Medical University
- Farydak (panobinostat) / Secura Bio
Clinical: A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Feb 10, 2013
P2, N=0, Withdrawn, Sponsor: SCRI Development Innovations, LLC
N=140 --> 219 N=46 --> 0
- carfilzomib / Generic mfg.
Clinical: A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis (clinicaltrials.gov) - Feb 10, 2013
P1, N=42, Recruiting, Sponsor: Academic Myeloma Consortium
- || Rituxan (rituximab) / Roche
New P3 trial: Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenstr (clinicaltrials.gov) - Feb 7, 2013
P3, N=380, Recruiting, Sponsor: University of Ulm